A board-certified medical oncologist with Atlantic Hematology Oncology, Atlantic Medical Group, Dr. Alistar is also a Medical Director of the Phase I Breakthrough Treatment Center.
At the center, her research focuses on immune-oncology and cancer metabolism in gastrointestinal cancer such as pancreatic tumors, cholangiocarcinoma, colorectal, esophageal, gastric cancer and hepatocellular carcinoma. Her clinical research projects involve active collaboration with other departments—from radiation oncology and surgical oncology to genomics and medical departments.
She is an accomplished researcher actively publishing in the field. She recently published in Lancet Oncology the results of a Phase I clinical study in pancreatic cancer that are very promising for advancing the field for pancreatic cancer—TrialSite News covered news of the study’s novel agent—CPI-613.
Dr. Alistar comes to Atlantic Health System from Wake Forest School of Medicine where she had a heavy emphasis on clinical trials and clinical research. At Wake Forest, she led the GI oncology disease oriented team as a gastrointestinal medical oncology physician and researcher, bringing cutting-edge treatments to patients. She designed, secured funding for and conducted five investigator-initiated therapeutic clinical trials, with four of them being phase one. Her work involved maintenance of a sponsor-investigator investigational new drug. She is passionate about Precision Oncology and Immunotherapies and seeks to identify novel treatment strategies for her patients. Past positions at Wake Forest include being a member of the Translational Cancer Genomics Committee, the GI Tumor Board, Internal Medicine Grand Rounds, and the Hepatobiliary Oncology Committee.
She is a member of several health care organizations, such as the American Society of Clinical Oncology, the American Society of Hospice and Palliative Care Medicine, and the American Society of Hematology, among many others. As well, she is a member and advisor for several other health care institutions. She was recently awarded the “Danny Danielson Translational Innovation Award” by Hoosier Cancer Research Network for her commitment to clinical research. Dr. Alistar received her medical degree from University of Medicine and Pharmacy, Cluj Napoca, Romania and her residency at Englewood Hospital and Medical Center, NJ, where she was chief resident.
Dr. Alistar received her medical degree from University of Medicine and Pharmacy, Cluj Napoca, Romania and her residency at Englewood Hospital and Medical Center, NJ, where she was chief resident. After her residency, she completed hematology oncology fellowship at Mount Sinai School of Medicine, Tisch Cancer Institute. She is affiliated with Atlantic Medical Group, and is a participating provider of Atlantic Accountable Care Organization, and sees patients at Morristown Medical Center.